Biotechnology company Abivax has enrolled its first patient in a phase 3 trial of Obefazimod, a treatment for severe ulcerative colitis, according to an Oct. 11 press release sent to Becker’s.
Abivax enrolls first patient in phase 3 ulcerative colitis drug trial
